Document is current
Any future updates will be listed below
-
Authors
Rossetti, Renata Ariza Marques https://orcid.org/0000-0003-0283-0975
Tordesillas, Leticia https://orcid.org/0000-0002-4643-7553
Beatty, Matthew S
Cianne, Junior https://orcid.org/0000-0003-3929-2613
Martinez Planes, Elena https://orcid.org/0009-0006-3220-5395
Du, Dongliang https://orcid.org/0000-0002-0881-7563
Snedal, Sebastian https://orcid.org/0000-0002-0771-7923
Wang, Chao https://orcid.org/0000-0001-7722-1782
Perez, Bradford A https://orcid.org/0000-0001-5725-195X
Berglund, Anders https://orcid.org/0000-0002-0393-3530
Chen, Yian Ann
Sarnaik, Amod https://orcid.org/0000-0002-2337-5898
Mulé, James J https://orcid.org/0000-0001-7354-0516
Creelan, Benjamin
Pilon-Thomas, Shari https://orcid.org/0000-0001-7785-3034
Abate-Daga, Daniel https://orcid.org/0000-0002-2571-0215
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05681780 at ClinicalTrials.govnct01005745 at ClinicalTrials.govDocuments that mention this clinical trial
461 Leveraging tumor infiltrating B-cells to enhance TIL immunotherapy using CD40 and 41BB agonism
https://doi.org/10.1136/jitc-2024-sitc2024.0461
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
nct01659151 at ClinicalTrials.govDocuments that mention this clinical trial
384 An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy
https://doi.org/10.1136/jitc-2021-sitc2021.384
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct01701674 at ClinicalTrials.govDocuments that mention this clinical trial
385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)
https://doi.org/10.1136/jitc-2021-sitc2021.385
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct02652455 at ClinicalTrials.govDocuments that mention this clinical trial
385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)
https://doi.org/10.1136/jitc-2021-sitc2021.385
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct01005745 at ClinicalTrials.govDocuments that mention this clinical trial
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct01659151 at ClinicalTrials.govDocuments that mention this clinical trial
384 An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy
https://doi.org/10.1136/jitc-2021-sitc2021.384
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct01701674 at ClinicalTrials.govDocuments that mention this clinical trial
385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)
https://doi.org/10.1136/jitc-2021-sitc2021.385
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct02652455 at ClinicalTrials.govDocuments that mention this clinical trial
385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)
https://doi.org/10.1136/jitc-2021-sitc2021.385
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
https://doi.org/10.1136/jitc-2023-007288
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct05681780 at ClinicalTrials.govDocuments that mention this clinical trial
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
67 A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: a retrospective analysis
https://doi.org/10.1136/jitc-2024-sitc2024.0067
nct05681780 at ClinicalTrials.govDocuments that mention this clinical trial
461 Leveraging tumor infiltrating B-cells to enhance TIL immunotherapy using CD40 and 41BB agonism
https://doi.org/10.1136/jitc-2024-sitc2024.0461
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
Documents that mention this clinical trial
461 Leveraging tumor infiltrating B-cells to enhance TIL immunotherapy using CD40 and 41BB agonism
https://doi.org/10.1136/jitc-2024-sitc2024.0461
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
https://doi.org/10.1136/jitc-2024-011066
-
Funding
Funding for this research was provided by:
Cancer Center Support Grant (P30-CA076292)
SuzyQ Melanoma Fund (N/A)
Shultz Family Foundation (N/A)
Moffitt Lung Cancer Center of Excellence (N/A)
Moffitt Melanoma Center of Excellence (N/A)
Mark Foundation For Cancer Research (N/A)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (N/A)
- License Information
